Homologous Recombination Deficiency
20
5
7
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
15.0%
3 terminated out of 20 trials
40.0%
-46.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (20)
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
Bipolar Androgen Therapy + Carboplatin in mCRPC
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
Functional Analysis of BRCAness
The HER Project: HRD in EGFR-mutated NSCLC
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Olaparib in Patients With HRD Malignant Mesothelioma
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
HRD and Resistance to PAPPi in EOC Patients
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
A Training Set for the HRD Model in EOC
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer